{
    "ticker": "PHGE.U",
    "name": "Phage Holdings Corp.",
    "description": "Phage Holdings Corp. is an innovative biotechnology company focused on the development and commercialization of bacteriophage-based therapeutics. Founded in 2019, the company aims to address antibiotic resistance\u2014a growing global health crisis\u2014by utilizing bacteriophages, which are viruses that specifically target and kill bacteria. This approach represents a novel treatment paradigm that offers significant advantages over traditional antibiotics, including specificity, efficacy against resistant strains, and reduced side effects. Phage Holdings is committed to advancing the science of phage therapy through rigorous research and clinical trials. Their proprietary platform is designed to identify, isolate, and characterize effective phages for various bacterial infections. In addition to therapeutic applications, the company is exploring the use of phages in food safety and agricultural settings. With a team of experienced scientists and industry veterans, Phage Holdings is at the forefront of phage research, collaborating with academic institutions and healthcare providers to bring new solutions to market. The company's mission is to improve patient outcomes and public health by providing innovative therapies that tackle one of the most pressing challenges in modern medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2019",
    "website": "https://www.phageholdings.com",
    "ceo": "Dr. Aimee J. Dorr",
    "social_media": {
        "twitter": "https://twitter.com/PhageHoldings",
        "linkedin": "https://www.linkedin.com/company/phage-holdings/"
    },
    "investor_relations": "https://www.phageholdings.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Aimee J. Dorr",
            "position": "CEO"
        },
        {
            "name": "Dr. Steven J. M. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Bacteriophage Therapy",
                "Phage-Based Antimicrobials"
            ]
        },
        {
            "category": "Research Services",
            "products": [
                "Phage Isolation and Characterization"
            ]
        }
    ],
    "seo": {
        "meta_title": "Phage Holdings Corp. | Pioneering Bacteriophage Therapies",
        "meta_description": "Explore Phage Holdings Corp., a leader in bacteriophage-based therapeutics aimed at combating antibiotic resistance and improving health outcomes.",
        "keywords": [
            "Phage Holdings",
            "Bacteriophage Therapy",
            "Antibiotic Resistance",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Phage Holdings known for?",
            "answer": "Phage Holdings is known for developing bacteriophage-based therapeutics to combat antibiotic-resistant infections."
        },
        {
            "question": "Who is the CEO of Phage Holdings?",
            "answer": "Dr. Aimee J. Dorr is the CEO of Phage Holdings Corp."
        },
        {
            "question": "Where is Phage Holdings headquartered?",
            "answer": "Phage Holdings is headquartered in New York, New York, USA."
        },
        {
            "question": "What products does Phage Holdings offer?",
            "answer": "Phage Holdings offers bacteriophage therapies and research services for phage isolation and characterization."
        },
        {
            "question": "When was Phage Holdings founded?",
            "answer": "Phage Holdings was founded in 2019."
        }
    ],
    "competitors": [
        "AMRX",
        "GILD",
        "VIR"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "BNTX",
        "PFE"
    ]
}